Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Prolor Biotech has received $1.7m grant from the Israeli Office of the Chief Scientist (OCS) to support hGH-CTP development program.
Subscribe to our email newsletter
The fund has been granted to the Israeli R&D subsidiary of Prolor for the biobetter version of human growth hormone, hGH-CTP.
Prolor is responsible to pay back the OCS the sum of the grant plus accrued interest through a series of payments that would begin only when hGH-CTP or other products that Prolor develops with its CTP technology begin to generate commercial revenues.
The Phase II trial of hGH-CTP showed reduction in the required hGH dosing frequency from the one injection per day required currently to a single weekly injection.
The company intends to begin a Phase III trial of hGH-CTP in adults with growth hormone deficiency in 2012.